Here’s What Boosted ClearPoint Neuro (CLPT) in Q3

Deep Sail Capital, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The fund returned 5.8% net of fees in the third quarter, outperforming the Russell 2000 Mid Cap Growth Index’s 0.4% return and lagging the Russell 2000 Index’s 12.4% gain. YTD, the fund returned 18.1% net of fees compared to 10.2% and 10.4% for the indexes. The long portfolio contributed to the fund’s performance in the quarter, while the short portfolio lagged amid the market’s fervor. For more information on the fund’s top picks in 2025, please check its top five holdings.

In its third-quarter 2025 investor letter, Deep Sail Capital highlighted stocks such as ClearPoint Neuro, Inc. (NASDAQ:CLPT). ClearPoint Neuro, Inc. (NASDAQ:CLPT) is a medical device company that focuses on the development of platforms for performing minimally invasive surgical procedures. The one-month return for ClearPoint Neuro, Inc. (NASDAQ:CLPT) was -11.07%, and its shares gained 4.30% over the last 52 weeks. On December 04, 2025, ClearPoint Neuro, Inc. (NASDAQ:CLPT) stock closed at $14.06 per share, with a market capitalization of $418.261 million.

Deep Sail Capital stated the following regarding ClearPoint Neuro, Inc. (NASDAQ:CLPT) in its third quarter 2025 investor letter:

“The largest contributors in Q3 were long-held microcap positions Kraken Robotics and ClearPoint Neuro, Inc. (NASDAQ:CLPT). Clearpoint also had another major confirmatory new event. uniQure (QURE) announced very strong trial results for its gene therapy AMT-130 in treating Huntington’s disease. The phase 2 study reported a ~75% slowing of disease progression over three years, which suggests that it might be a major step in the direction of curing Huntington’s disease. ClearPoint Neuro provides the SmartFlow Cannula system that uniQure will use for those treatments, and ClearPoint will benefit materially. uniQure will likely be the first major neurological cell & gene therapy approved for one of the major neurological diseases. This is huge for Clearpoint and will mean significant milestone revenues as well as heavy usage of their SmartFlow system in the years to come.”

ClearPoint Neuro, Inc. (NASDAQ:CLPT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 10 hedge fund portfolios held ClearPoint Neuro, Inc. (NASDAQ:CLPT) at the end of the third quarter, the same as in the previous quarter. While we acknowledge the risk and potential of ClearPoint Neuro, Inc. (NASDAQ:CLPT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ClearPoint Neuro, Inc. (NASDAQ:CLPT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.